Healthcare - Biotechnology - NASDAQ - US
$ 1.98
-4.81 %
$ 29.4 M
Market Cap
-0.22
P/E
CASH FLOW STATEMENT
-19 M
OPERATING CASH FLOW
8.19 M
INVESTING CASH FLOW
5.26 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Longeveron Inc.
| Net Income | -21.4 M |
| Depreciation & Amortization | 946 K |
| Capital Expenditures | -694 K |
| Stock-Based Compensation | 2.03 M |
| Change in Working Capital | -1.08 M |
| Others | 439 K |
| Free Cash Flow | -19.7 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (21.4) | (18.8) | (17.0) | (3.7) | (3.0) | (6.3) |
| Depreciation & Amortization | 0.9 | 0.9 | 0.9 | 0.8 | 0.8 | 0.7 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (2.0) | 0 |
| Stock Based Compensation | 2.0 | 2.2 | 7.7 | 83 K | 0.1 | 0.4 |
| Other Operating Activities | 0.5 | 1.4 | (0.2) | 44 K | 2.0 | 1.9 |
| Change in Working Capital | (1.1) | 0.2 | (1.1) | 0.5 | (0.3) | 11.2 K |
| Cash From Operations | (19.0) | (14.0) | (9.6) | (2.4) | (2.4) | (5.2) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.7) | (0.9) | (1.3) | (0.3) | (0.1) | (0.2) |
| Other Items | 8.9 | 0.2 | (9.4) | 0 | 0 | 0 |
| Cash From Investing Activities | 8.2 | (0.7) | (10.7) | (0.3) | (0.1) | (0.2) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | (0.3) | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | (0.2) | 0.5 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 76 K | (0.5) | 0.2 | 12.7 K | 0.3 | 1.4 |
| Cash From Financing Activities | 5.3 | (0.5) | 45.2 | 1.6 | 0.3 | 1.4 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (5.6) | (15.2) | 24.8 | (1.1) | (2.2) | (4.0) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (19.7) | (14.8) | (10.9) | (2.6) | (2.5) | (5.4) |